{
    "clinical_study": {
        "@rank": "124534", 
        "arm_group": {
            "arm_group_label": "women with HER-2 driven IBC at least Stage IIIA", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial will be determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in\n      high risk HER-2 high and intermediate expression breast cancers. Subjects will have HER-2\n      driven IBC at least Stage IIIA with N2 following chemotherapy with/without trastuzumab or\n      recurrence exclusive of new primary tumor b0ut rendered NED. Mammogram, laboratory studies,\n      CT, and leukapheresis will be performed, in addition to vaccine administration."
        }, 
        "brief_title": "Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women over Age 18 years.\n\n          -  Subjects with Invasive Breast Cancer at least Stage IIIA N2 (4 positive nodes) or\n             have recurrent metastatic breast cancer rendered NED by any means that are classic\n             HER-2 3+ 30%, 2+ IHC and FISH positive or HER-2 2+ FISH negative verified by the\n             Department of Pathology at the Hospital of the University of Pennsylvania that have\n             completed chemotherapy and/or trastuzumab and are within 1 year from there last\n             treatment and have no evidence of disease. 3. Patients deemed to require\n             anti-estrogen therapy for treatment of their breast cancer can continue anti-estrogen\n             therapy during vaccinations 4. Women of childbearing age with a negative pregnancy\n             test documented prior to enrollment. 5. Subjects with ECOG Performance Status Score\n             of 0 or 1 (Appendix D). 6. Subjects willing to use birth control if necessary 7.\n             Subjects who have voluntarily signed a written Informed Consent in accordance with\n             institutional policies after its contents have been fully explained to them.\n\n        Key exclusion criteria\n\n        1. Pregnant or lactating females. 2. Subjects with positive HIV or hepatitis C at baseline\n        by report. 3.\n\n        Subjects with coagulopathies, including thrombocytopenia with platelet count 75,000, INR\n        1.5 and partial thromboplastin time 50 sec 4. Subjects with major cardiac illness MUGA 50%\n        EF. 5. Subjects with pre-existing medical illnesses or medications which might interfere\n        with the study as determined by PI."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110173", 
            "org_study_id": "UPCC 25113"
        }, 
        "intervention": {
            "arm_group_label": "women with HER-2 driven IBC at least Stage IIIA", 
            "intervention_name": "HER-2 pulsed DC1 vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Brian Czerniecki, MD, PhD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Brian Czerniecki, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Brian Czerniecki, MD, PhD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Brian Czerniecki, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110173"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}